General MedicationsINJECTIONGeneric
VITRASE
HYALURONIDASE
Standard Dose
6,200 UNITS/VIAL
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary
Approval overview VITRASE is listed in Drugs@FDA under application 021640 (BLA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient HYALURONIDASE Form and strength INJECTABLE;INJECTION - 6,200 UNITS/VIAL Sponsor BAUSCH AND LOMB Submission history Latest submission status date: 2024-01-12 00:00:00.
Structured Monograph
Clinical summary
Approval overview VITRASE is listed in Drugs@FDA under application 021640 (BLA). Review priority: STANDARD Marketing status: Discontinued Active ingredient HYALURONIDASE Form and strength INJECTABLE;INJECTION - 6,200 UNITS/VIAL Sponsor BAUSCH AND LOMB Submission history Latest submission status date: 2024-01-12 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.